Macter International Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is to manufacture and market pharmaceutical products. The Company’s business areas include contract manufacturing and branded generic formulations. It is a contract manufacturer for multinational companies, which offers a range of dosage forms: oral solids and liquids, parenteral (ampules and vials), topicals, metered dose inhalers, ear and eye drops. Its contract manufacturing clients include a number of blue-chip multinationals. Its diversified portfolio covers various therapeutic categories, including Antibiotics, Anti-allergy, cardiovascular, Anti-viral and other. Its products include DX3 Softgel, Macdronic 5mg, Macdronic 4mg, MAclimta , Milast, MACIVY, MACLINZA, Avelia Sachet, SANTE IV, Maclusa, Nurica, Alenor, Atizox, Bismol, Buphain, Cadla, Carac, Carac-H, Co-Amoxi, Dexodine, Demeco, Dicaine, DX3 Softgel, Ecavir, Epilepsin, Epuram, Esante, Glio, Hart, and other.
Metrics to compare | MACT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMACTPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.0x | −0.6x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | 0.0x | 1.5x | 2.6x | |
Price / LTM Sales | 0.0x | 4.8x | 3.1x | |
Upside (Analyst Target) | 0.0% | 45.2% | 57.6% | |
Fair Value Upside | Unlock | 4.5% | 7.3% | Unlock |